What Dicron (Gliclazide) Treats: Main Uses and Benefits

Dicron (Gliclazide) is relevant in contexts involving heightened systemic burden, generally used as part of symptomatic management in chronic conditions.

---

Treating Type 2 Diabetes Mellitus

This agent is commonly used to treat Type 2 Diabetes Mellitus in adult patients when initial efforts like disciplined dietary changes and regular physical activity are insufficient. It is applied in conditions where functional stability becomes affected and is considered relevant as a step in chronic disease management.

---

Correcting Uncontrolled Hyperglycemia

The medication is used for managing symptoms related to elevated blood glucose (hyperglycemia). It is relevant for easing symptoms that interfere with daily comfort by supporting the stabilization of both fasting and postprandial blood glucose levels, and may assist with managing metrics like Glycosylated Hemoglobin (HbA1c).

“The medication helps ease symptoms that interfere with daily comfort by supporting the stabilization of blood sugar levels.”

---

Supporting Long-Term Well-being

By contributing to sustained glycemic control, the medication offers a relevant long-term benefit. Supporting stabilization may assist with managing the risk of serious, long-term complications affecting the heart, eyes, and kidneys associated with chronic high sugar, and helps maintain a sense of stability when symptoms are more noticeable.

---

Quick Fact: Relief for Hyperglycemia The primary use is to help manage the measurable symptom of chronically high blood sugar.

Gliclazide is officially approved for use in adult patients with Type 2 Diabetes Mellitus when glycemic control cannot be achieved by diet and exercise alone. Use in older adults is generally permitted, though close clinical supervision may be warranted.

Contraindicated Populations

The medicine is contraindicated and must not be used by several populations. This includes patients with Type 1 Diabetes Mellitus, diabetic ketoacidosis or coma, and documented hypersensitivity to gliclazide, other sulfonylureas, or sulfonamides. Use is also formally prohibited in cases of severe hepatic insufficiency or severe renal insufficiency.

Use is contraindicated during pregnancy and while breastfeeding. The co-administration of Gliclazide with Miconazole (via systemic route or oromucosal gel) is also formally prohibited.

Age and Condition Limitations

Safety and effectiveness in pediatric patients (under 18 years) have not been established, and the medicine is therefore not recommended in this age group.

For patients with mild to moderate kidney or liver impairment, use may be permitted but requires careful monitoring. Additional restrictions apply during periods of acute stress (such as severe infection, trauma, or surgery), which officially mandate a temporary switch to insulin therapy.

Gliclazide's interaction profile is defined by combinations that either significantly potentiate or antagonize its effect on blood glucose, or alter the drug’s presence in the body as established by regulatory authorities.

The co-administration of Miconazole (systemic route or oromucosal gel) is formally contraindicated due to the high, documented risk of severe potentiation of the glucose-lowering effect.

Multiple medicinal product categories may potentiate the hypoglycaemic effect of Gliclazide, thereby increasing the risk of low blood sugar. These include other antidiabetic agents, Beta-blockers, ACE Inhibitors, and certain antifungals such as Fluconazole. Conversely, official labeling notes that substances with a diabetogenic effect, such as Glucocorticoids and Danazol, antagonize Gliclazide's action by increasing blood glucose levels.

Pharmacokinetic interactions are documented with agents that modify Gliclazide's plasma concentration. Phenylbutazone is classified as a combination not recommended because it increases Gliclazide exposure by displacing plasma protein binding and reducing elimination. The herbal product St. John’s Wort is also officially noted to decrease Gliclazide exposure, potentially resulting in a loss of blood glucose control. Alcohol is considered a combination not recommended due to its potentiation of the hypoglycaemic effect.

Interactions are documented as being more severe in specific populations: the risk of severe hypoglycaemic reactions is increased in patients with severe renal or hepatic impairment. Additionally, when co-administered with Fluoroquinolones, there is a noted risk of dysglycaemia, especially in elderly patients.

Gliclazide is an Insulin Secretagogue that exerts its primary action by targeting the Sulfonylurea Receptor 1 (SUR1), a subunit of the ATP-sensitive potassium channel ( K ATP channel) on the pancreatic beta-cell membrane. Binding to SUR1 causes the K ATP channel to close, which inhibits the efflux of potassium ions ( K^+) from the cell. This molecular event leads to the depolarization of the cell membrane, subsequently activating voltage-dependent calcium channels (VDCCs).

The resulting influx of calcium ions ( Ca^2+) acts as the final intracellular signal, initiating the rapid exocytosis of stored insulin into the systemic circulation. This surge in circulating insulin enhances glucose uptake by peripheral tissues and suppresses hepatic glucose production, completing the insulin secretagogue mechanistic cascade.

Separately, Gliclazide possesses K ATP-independent properties, including antioxidant activity and the modulation of platelet adhesion. This mechanism engages specific pathways to influence vascular and hemobiological integrity.

How to Use Dicron (Gliclazide)

This section details the standardized administration protocols for Gliclazide.

---

Official Administration Protocol

Gliclazide is consistently administered via the oral route as a tablet. The medication must be taken once daily, with the single dose coinciding with breakfast or the first main meal of the day. This required timing is essential to align the medicine's action with food intake.

Two main formulations are utilized: an Immediate-Release (IR) tablet and a Modified-Release (MR) tablet. The MR form, which is intended for once-daily use, must be swallowed whole and not be crushed or chewed to preserve its extended-action properties.

---

Standard Dosing and Schedule

Dosing Parameter	Modified-Release (MR) Tablet	Immediate-Release (IR) Tablet
Starting Dose (Daily)	30 mg (single dose)	40 mg to 80 mg
Maximum Dose (Daily)	120 mg (single dose)	320 mg (in divided doses)

Dose adjustments for the MR formulation are generally advised to occur in increments of 30 mg with an interval of at least one month to allow for assessment of metabolic response. For the IR formulation, daily doses exceeding 160 mg must be taken in divided doses.

Administration Management

The protocol for managing missed doses is to skip the forgotten dose entirely and resume the regular schedule the following day, strictly prohibiting the doubling of the dose. For older adults (aged 65 years and over), starting with the minimum daily dose (30 mg MR) is recommended with careful monitoring. Efficacy and safety have not been established in the pediatric population.

Gliclazide is a sulfonylurea medication prescribed for the management of Type 2 Diabetes Mellitus (T2DM). Recent clinical evidence has focused heavily on its efficacy in glycemic control, its microvascular benefits, and its safety profile compared to other similar medications.

Efficacy and Microvascular Outcomes

Clinical trials, notably the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial, have provided key evidence. This large study showed that a gliclazide-based intensive glucose control regimen was associated with a significant reduction in the composite outcome of major macrovascular and microvascular events.

• Renal Protection: A primary finding of ADVANCE was the evidence of enhanced renal protection, driven by a reduction in the incidence of nephropathy (kidney disease) compared to standard glucose control. This effect persisted in long-term follow-up studies.

Glycemic Control and Hypoglycemia Risk

Gliclazide has been shown to be effective in lowering Glycated Hemoglobin (HbA1c) levels, which is the primary metric for long-term glycemic management in T2DM. Comparative studies suggest that gliclazide achieves comparable efficacy to other oral glucose-lowering agents.

Safety Metric	Research Findings (Compared to Other Sulfonylureas)
Hypoglycemia Risk	Consistently reports a lower incidence of severe hypoglycemia.
Cardiovascular Risk	Observational data and non-cardiovascular outcome trials suggest a more favorable or neutral cardiovascular safety profile.

Cardiovascular Safety Profile

While dedicated cardiovascular outcome trials for gliclazide are limited, large-scale studies and meta-analyses suggest that the drug is not associated with an increased risk of adverse cardiovascular events or mortality when compared to certain other sulfonylureas. This is a significant consideration, particularly for patients with T2DM who are at an increased risk for cardiovascular complications.

Common questions about Dicron (Gliclazide) (FAQ)

Q: How quickly does Dicron (Gliclazide) start working?

Official documents note that certain temporary visual changes may occur, particularly when treatment is initiated. These transient disturbances are noted to be associated with fluctuations in blood glucose levels.

Q: How long do the effects of Dicron (Gliclazide) last?

The Modified-Release ( MR) formulation of Gliclazide is specifically designed to control the release of the active compound over an extended period. This design is intended to support a once-daily dosing regimen.

Q: Why do some people call Gliclazide a 'sulfur drug'?

This medication belongs to the sulfonylurea class of antidiabetic agents. Official labeling notes that Gliclazide is contraindicated in patients with known hypersensitivity not only to the drug itself but also to other sulfonylureas or related sulfonamides.

Q: Are there common signs of low blood sugar from Dicron (Gliclazide)?

Yes, hypoglycaemia (low blood sugar) is the primary and most common adverse reaction documented. Possible symptoms listed in regulatory documents include headache, intense hunger, nausea, confusion, tremor, sweating, clammy skin, and anxiety.

Q: What is the difference between Dicron and other diabetes pills like Glipizide?

Gliclazide is classified as a second-generation sulfonylurea derivative. Research evidence suggests that Gliclazide is associated with a lower incidence of severe hypoglycemia in comparisons with certain other sulfonylurea medications.

Q: Are there long-term side effects associated with Dicron (Gliclazide) use?

Adverse reactions are classified by frequency based on official documentation. The main risk associated with its use is hypoglycaemia. Gastrointestinal disorders, such as abdominal pain, nausea, or diarrhoea, are classified as uncommon side effects.

Q: Can I take Dicron (Gliclazide) if I have had a history of heart attack?

Regulatory documents note that in cases of severe vascular disease, including serious coronary heart disease, cautious use and careful monitoring are generally necessary. The use of the minimum daily dose may be specified as a precaution in official documents.

Q: What does 'sulfonylurea' mean in simple terms?

Gliclazide is an Oral Hypoglycemic Agent of the sulfonylurea class. Its primary function is as an Insulin Secretagogue, which means it works by stimulating the beta-cells in the pancreas to release stored insulin into the bloodstream.

Q: Can Dicron (Gliclazide) be taken with Metformin?

Yes, regulatory documents state that Gliclazide is often used in combination with other antidiabetic agents, including Metformin. This combination requires precautions for use because these agents may potentiate (strengthen) the blood glucose lowering effect.

Q: Is Dicron (Gliclazide) known to cause weight gain?

Weight gain is not explicitly classified as a common, uncommon, or rare side effect of Gliclazide in regulatory safety tables. Side effects are classified based on the frequency with which they are reported in clinical trials and post-marketing surveillance.

Q: Does Dicron (Gliclazide) interact with over-the-counter pain relievers?

Regulatory documents note that the hypoglycaemic effect of Gliclazide may be potentiated (increased) by drugs belonging to the Non-Steroidal Anti-Inflammatory Drug ( NSAID) class, such as Phenylbutazone. This combination is noted in regulatory documents as one that requires precautions.

Q: Is Dicron (Gliclazide) available in different tablet strengths?

Yes, official product information confirms that Gliclazide is manufactured in various tablet strengths. Examples include the Immediate-Release ( IR) tablets of 80 mg and the Modified-Release ( MR) tablets of 30 mg and 60 mg.

Q: Does Dicron (Gliclazide) have a generic version?

The active compound is Gliclazide, and the product is available under both branded and generic names. Official product information confirms that generic versions are available for both the Immediate-Release and the Modified-Release forms.

Q: Is it true that Dicron (Gliclazide) is used in combination therapies?

Yes. Regulatory documents classify combination with other antidiabetic agents, such as metformin, insulins, or DPP-4 inhibitors, as a combination requiring precautions for use. This indicates its use in multi-drug regimens.

Q: What ingredients are in the Dicron (Gliclazide) tablet besides the main drug?

Official regulatory labeling contains a detailed list of inactive ingredients, known as excipients, that are used in the tablet formulation. These excipients are combined with the single active compound, Gliclazide.

Q: Why are some Gliclazide tablets scored (have a line on them)?

Official product information notes that certain tablet strengths are manufactured with a score line. Examples include the 80 mg Immediate-Release tablet and the 60 mg Modified-Release tablet.

Q: Does Dicron (Gliclazide) cause fatigue?

Rare side effects affecting the blood, such as a low number of red blood cells ( anaemia), are documented in official safety information. Signs of this condition can include feeling tired ( fatigue) or weakness.

Q: Can I take aspirin with Dicron (Gliclazide)?

Salicylates, which include Aspirin, are documented in regulatory resources as drugs that may potentiate (increase) the glucose-lowering effect of sulfonylureas. The combination is noted in regulatory resources as one that requires precautions.

Storage and Disposal Requirements for Dicron (Gliclazide)

Official Storage Conditions

Dicron (Gliclazide) tablets must be stored at no higher than 25 C (77°F), as required by regulatory labeling. The medicine should be kept out of the sight and reach of children to prevent accidental exposure.

To maintain stability, the tablets must be protected from both moisture and light and should ideally be stored in the original container until use.

---

Instructions for Disposal

Unused or expired Gliclazide must be discarded strictly in accordance with local pharmaceutical waste requirements.

Regulatory guidance specifies that this medicine should not be disposed of in household waste or wastewater to mitigate environmental risks. Consult local drug take-back programs for proper handling.